| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Autophagy pathway (as a control). The active Tat-beclin 1 peptide is derived from beclin 1, a key regulator of autophagy. It induces autophagy by binding to HIV-1 Nef and interacting with GAPR-1. The scrambled control has a randomized amino acid sequence, rendering it inactive in inducing autophagy.
|
|---|---|
| ln Vitro |
The active Tat-beclin 1 peptide reduces the accumulation of polyglutamine-expanded protein aggregates and the replication of several pathogens, such as HIV. It also reduces mortality in mice infected with chikungunya or West Nile virus. The scrambled control is used to verify that these effects are specifically due to the beclin 1-derived sequence.
|
| ln Vivo |
In vivo, the scrambled control is used alongside the active peptide. The active peptide has been shown to reduce pathogen replication and improve survival in infected mice. The scrambled control, having a randomized sequence, should have no effect on these outcomes, allowing researchers to attribute the effects to the specific beclin 1 sequence.
|
| Enzyme Assay |
Not applicable for the control. For the active peptide, binding to GAPR-1 and Nef could be assessed by SPR or pull-down assays. The scrambled control should show minimal binding to these targets, confirming the specificity of the interaction.
|
| Cell Assay |
Autophagy induction assay: Cells (e.g., HeLa or GFP-LC3 reporter cells) are seeded in 6-well plates. Cells are treated with Tat-beclin 1 or its scrambled control (0.1-10 uM) for 4-24 h. Autophagy is assessed by: 1) Immunofluorescence for LC3 puncta (autophagosomes), 2) Western blotting for LC3-II conversion, and 3) p62 degradation. The scrambled control should not increase LC3-II levels or LC3 puncta compared to vehicle.
|
| Animal Protocol |
Mouse model of viral infection: Mice are infected with a pathogen (e.g., chikungunya virus) and then treated with Tat-beclin 1 or the scrambled control peptide (1-10 mg/kg, i.p., daily). Viral load is measured in blood and tissues. Survival curves are plotted. The scrambled control serves as the negative control to ensure that any reduction in viral load is due to specific induction of autophagy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for the scrambled control are limited. As a Tat-conjugated peptide (MW 3855.12, TFA salt), it has a short plasma half-life (minutes) due to rapid proteolytic degradation. It is water-soluble and is typically administered via intraperitoneal injection. The TFA salt enhances stability and solubility for in vivo studies.
|
| Toxicity/Toxicokinetics |
Toxicity data for the scrambled control are not reported. As a Tat-conjugated peptide, it may exhibit some cellular uptake, but the scrambled sequence is not expected to induce autophagy or cause specific toxicities. It is intended for research use only and not for human therapeutic applications. Standard safety precautions for handling peptides should be observed.
|
| References | |
| Additional Infomation |
Tat-beclin 1 scrambled TFA is a research-grade negative control peptide for studying autophagy. It is not a drug candidate and has no therapeutic indications. The TFA salt is used to enhance stability. For research use only. Store as powder at -20degC, sealed and away from moisture.
|
| Molecular Formula |
C164H251N57O45
|
|---|---|
| Molecular Weight |
3855.12
|
| Related CAS # |
Tat-beclin 1 scrambled
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~25 mg/mL (~6.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2594 mL | 1.2970 mL | 2.5940 mL | |
| 5 mM | 0.0519 mL | 0.2594 mL | 0.5188 mL | |
| 10 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
